Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
6 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Flow cytometric minimal residual disease measurement accounting for cytogenetics in children with non-high-risk acute lymphoblastic leukemia treated according to the ALL-MB 2008 protocol.
Cancer Med. 2024 Apr;13(8):e7172. doi: 10.1002/cam4.7172.
Cancer Med. 2024.
PMID: 38651186
Free PMC article.
A simple procedure to identify children with B-lineage acute lymphoblastic leukemia who can be successfully treated with low or moderate intensity: Sequential versus single-point minimal residual disease measurement.
Popov A, Henze G, Roumiantseva J, Budanov O, Belevtsev M, Verzhbitskaya T, Boyakova E, Movchan L, Tsaur G, Fadeeva M, Lagoyko S, Zharikova L, Miakova N, Litvinov D, Khlebnikova O, Streneva O, Stolyarova E, Ponomareva N, Novichkova G, Fechina L, Aleinikova O, Karachunskiy A.
Popov A, et al. Among authors: budanov o.
Pediatr Blood Cancer. 2023 Jun;70(6):e30295. doi: 10.1002/pbc.30295. Epub 2023 Mar 28.
Pediatr Blood Cancer. 2023.
PMID: 36975157
Item in Clipboard
Flow cytometric MRD at the end of consolidation in childhood B-lineage acute lymphoblastic leukemia has significant prognostic value but limited clinical implications: Results of study ALL-MB 2008.
Popov A, Henze G, Roumiantseva J, Budanov O, Verzhbitskaya T, Boyakova E, Tsaur G, Fadeeva M, Lagoyko S, Zharikova L, Miakova N, Litvinov D, Khlebnikova O, Streneva O, Ponomareva N, Novichkova G, Fechina L, Karachunskiy A.
Popov A, et al. Among authors: budanov o.
Leuk Res. 2023 Feb;125:106998. doi: 10.1016/j.leukres.2022.106998. Epub 2022 Dec 16.
Leuk Res. 2023.
PMID: 36566537
No abstract available.
Item in Clipboard
A single flow cytometric MRD measurement in children with B-lineage acute lymphocytic leukemia and hyperleukocytosis redefines the requirements of high-risk treatment: Results of the study ALL-MB 2008.
Popov A, Henze G, Roumiantseva J, Budanov O, Belevtsev M, Verzhbitskaya T, Boyakova E, Movchan L, Tsaur G, Fadeeva M, Lagoyko S, Zharikova L, Miakova N, Litvinov D, Khlebnikova O, Streneva O, Stolyarova E, Ponomareva N, Novichkova G, Fechina L, Aleinikova O, Karachunskiy A.
Popov A, et al. Among authors: budanov o.
Leuk Res. 2022 Dec;123:106982. doi: 10.1016/j.leukres.2022.106982. Epub 2022 Oct 22.
Leuk Res. 2022.
PMID: 36332292
No abstract available.
Item in Clipboard
One-point flow cytometric MRD measurement to identify children with excellent outcome after intermediate-risk BCP-ALL: results of the ALL-MB 2008 study.
Popov A, Henze G, Roumiantseva J, Budanov O, Belevtsev M, Verzhbitskaya T, Boyakova E, Movchan L, Tsaur G, Fadeeva M, Lagoyko S, Zharikova L, Miakova N, Litvinov D, Khlebnikova O, Streneva O, Stolyarova E, Ponomareva N, Novichkova G, Fechina L, Aleinikova O, Karachunskiy A.
Popov A, et al. Among authors: budanov o.
J Cancer Res Clin Oncol. 2023 Jul;149(8):4629-4637. doi: 10.1007/s00432-022-04378-3. Epub 2022 Sep 28.
J Cancer Res Clin Oncol. 2023.
PMID: 36169717
Item in Clipboard
A simple algorithm with one flow cytometric MRD measurement identifies more than 40% of children with ALL who can be cured with low-intensity therapy. The ALL-MB 2008 trial results.
Popov A, Henze G, Roumiantseva J, Budanov O, Belevtsev M, Verzhbitskaya T, Boyakova E, Movchan L, Tsaur G, Fadeeva M, Lagoyko S, Zharikova L, Miakova N, Litvinov D, Khlebnikova O, Streneva O, Stolyarova E, Ponomareva N, Novichkova G, Fechina L, Aleinikova O, Karachunskiy A.
Popov A, et al. Among authors: budanov o.
Leukemia. 2022 May;36(5):1382-1385. doi: 10.1038/s41375-022-01542-z. Epub 2022 Mar 23.
Leukemia. 2022.
PMID: 35322171
No abstract available.
Item in Clipboard
Cite
Cite